Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04487444 · ClinicalTrials.gov registry record · Phase 2
Thymalfasin (Thymosin Alpha 1) to Treat COVID-19 Infection
A Phase 2 study, sponsored by Rhode Island Hospital.
- Terminated
- Registry status
- Phase 2
- Development phase
- 56
- Enrollment target
NCT04487444: Clinical Trial Phase 2 study, sponsored by Rhode Island Hospital.
NCT04487444 is a Phase 2 study that was terminated before completion, run by Rhode Island Hospital. The registered enrollment target is 56 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (58% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04487444, a Phase 2 study, was terminated before completion, sponsored by Rhode Island Hospital.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 56 participants
- Enrollment target
Study Summary
It is our hypothesis that a course of Ta1 administered to hospitalized individuals with COVID-19 infection and lymphocytopenia will improve the time to recovery (primary objective) and severity of infection (secondary objectives) compared to untreated individuals in the same hospital with comparable lymphocytopenia. After screening, hospitalized patients with COVID-19 and lymphocytopenia who meet the inclusion criteria will receive Ta1 (1.6 mg) administered subcutaneously (SC) daily for 1 week. Individuals in the control arm will be followed on the identical protocol but will not receive daily Ta1.
Primary Outcome
Length of time for patient to no longer require supplemental oxygen and can sustain a good oxygen saturation (SpO2) on room air
Interventions
- DRUG Thymalfasin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2020-09-10 |
| Est. Completion | 2023-02-03 |
| Phase | Phase 2 |
Why NCT04487444 stopped before completion
NCT04487444 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 56 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (58% lower).
The record links to 0 conditions, and to 1 intervention - of which Thymalfasin is the first listed.
NCT04487444 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04487444 about?
NCT04487444 is a clinical study titled "Thymalfasin (Thymosin Alpha 1) to Treat COVID-19 Infection". It is our hypothesis that a course of Ta1 administered to hospitalized individuals with COVID-19 infection and lymphocytopenia will improve the time to recovery (primary objective) and severity of infection (secondary objectives) compared to untreated individuals in the same hospital with comparable...
What is the current status of trial NCT04487444?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 56 participants. The study started on 2020-09-10. Estimated completion is 2023-02-03.
What interventions are being tested in trial NCT04487444?
The interventions under investigation include: Thymalfasin (DRUG).
Who is sponsoring clinical trial NCT04487444?
This trial is sponsored by Rhode Island Hospital, which has 130 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04487444's enrollment target sits among peer trials
56 1146th of 2000 higher than 848 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02287428 · 56 participants · Phase 1
Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM
- NCT02923011 · 56 participants · Phase 3
Comparative Effectiveness of MRgFUS Versus CTgRFA for Osteoid Osteomas
- NCT02935283 · 56 participants
Neuroimaging and Neuropsychological Outcomes in Urea Cycle Disorders
- NCT03375866 · 56 participants · NA
Effects of Mixed Nut Consumption on Satiety and Weight Management
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI